<div id="readability-page-1"><div> By Elias Schisgall <pre></pre> Shares of Capricor Therapeutics fell after the company posted a wider-than-expected loss in the fourth quarter after not bringing in any revenue. Shares were down 8.6% to $30.54 in Friday afternoon trading. The stock has more than doubled in value in the past year. The biotechnology company on Thursday posted a quarterly loss of $30.2 million, or 62 cents a share, compared with a loss of $7.12 million, or 16 cents a share, a year earlier. Capricor did not post any revenue during the quarter, compared with $11.1 million a year prior. The company said its primary sources of revenue were $40 million in upfront and first-development milestone payments and $10 million in second-development milestone payments per the company's distribution agreement with Nippon Shinyaku. Those payments were recognized as of year-end 2024, it said. Analysts surveyed by FactSet were expecting $500,000 in revenue and a loss of 51 cents a share. The company said it is continuing to work toward approval for Deramiocel to treat Duchenne muscular dystrophy. A biologics license application for the treatment is under review by the Food and Drug Administration, and the company expects a response from the agency by Aug. 22. <pre></pre> Write to Elias Schisgall at elias.schisgall@wsj.com <pre></pre> (END) Dow Jones Newswires March 13, 2026 14:48 ET (18:48 GMT)Copyright (c) 2026 Dow Jones &amp; Company, Inc.</div></div>

標普全球醫療股指數 ETF - iShares

生物科技 ETF - VanEck Vectors

醫藥突破 ETF - ALPS

Capricor Therapeutics 的股價下跌 8.6%，至 30.54 美元，此前報告第四季度虧損 3020 萬美元，遠超分析師預期的 50 萬美元收入和每股虧損 51 美分。該公司在本季度沒有產生任何收入，較去年同期的 1110 萬美元下降。Capricor 正在等待 FDA 對 Deramiocel 治療杜氏肌營養不良症的批准，預計將在 2026 年 8 月 22 日之前收到回覆

Capricor Therapeutics Falls on Wider-Than-Expected 4Q Loss

MorningStar

Capricor治療

紐交所高增長板生物技術指數 ETF - First Trust

動態生物技術與基因組 ETF - Invesco

Invesco Nasdaq Biotechnology ETF

醫療業 ETF - Vanguard

標普生物技術 3 倍做多 - Direxion

醫療業 ETF - SPDR

美國制藥 ETF - iShares

標普生物技術 ETF - SPDR

2 倍做多納斯達克生物技術 ETF - ProShares

基因改革 ETF - ARK

納斯達克生物科技指數 ETF - iShares Nasdaq

Capricor 治療公司因第四季度虧損幅度超出預期而股價下跌